Published in Proc Natl Acad Sci U S A on November 01, 1984
Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter. EMBO J (1986) 6.82
Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J (1987) 6.26
Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol (1990) 6.23
Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions. J Virol (1987) 6.20
Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. J Virol (1989) 5.67
U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2. Proc Natl Acad Sci U S A (1984) 5.27
Nucleotide sequences of mRNAs encoding Epstein-Barr virus nuclear proteins: a probable transcriptional initiation site. Proc Natl Acad Sci U S A (1986) 5.12
Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells. J Virol (1985) 4.76
Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol (1988) 4.55
Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J Virol (1987) 4.12
Promiscuous trans activation of gene expression by an Epstein-Barr virus-encoded early nuclear protein. J Virol (1986) 3.82
Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus. J Virol (1986) 3.65
A bicistronic Epstein-Barr virus mRNA encodes two nuclear proteins in latently infected, growth-transformed lymphocytes. J Virol (1987) 3.58
Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. J Virol (1987) 3.53
Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein. J Virol (1990) 3.24
Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Mol Cell Biol (1996) 3.22
Early events in Epstein-Barr virus infection provide a model for B cell activation. J Exp Med (1985) 3.19
Human herpesviruses: a consideration of the latent state. Microbiol Rev (1989) 3.15
A promoter for the highly spliced EBNA family of RNAs of Epstein-Barr virus. J Virol (1987) 3.10
Two related Epstein-Barr virus membrane proteins are encoded by separate genes. J Virol (1989) 3.09
Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells. EMBO J (1986) 3.07
Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J (1998) 3.01
Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J (1997) 2.87
In vitro transcriptional activation, dimerization, and DNA-binding specificity of the Epstein-Barr virus Zta protein. J Virol (1990) 2.84
Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci U S A (1991) 2.82
The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. J Virol (1991) 2.81
The truncated form of the Epstein-Barr virus latent-infection membrane protein expressed in virus replication does not transform rodent fibroblasts. J Virol (1988) 2.74
The Epstein-Barr virus (EBV) BZLF1 immediate-early gene product differentially affects latent versus productive EBV promoters. J Virol (1989) 2.65
Identification and mapping of Epstein-Barr virus early antigens and demonstration of a viral gene activator that functions in trans. J Virol (1986) 2.64
Definitive identification of a member of the Epstein-Barr virus nuclear protein 3 family. Proc Natl Acad Sci U S A (1986) 2.62
A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1. J Virol (1990) 2.60
Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23. J Virol (1990) 2.58
Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci U S A (1998) 2.49
Responsiveness of the Epstein-Barr virus NotI repeat promoter to the Z transactivator is mediated in a cell-type-specific manner by two independent signal regions. J Virol (1989) 2.43
Four virally determined nuclear antigens are expressed in Epstein-Barr virus-transformed cells. Proc Natl Acad Sci U S A (1986) 2.34
Expression of the Epstein-Barr virus nuclear protein 2 in rodent cells. J Virol (1986) 2.28
A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J Virol (1995) 2.28
A fifth Epstein-Barr virus nuclear protein (EBNA3C) is expressed in latently infected growth-transformed lymphocytes. J Virol (1988) 2.27
Distinction between Epstein-Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins. J Virol (1989) 2.23
An Epstein-Barr virus transforming protein associates with vimentin in lymphocytes. Mol Cell Biol (1987) 2.22
The Epstein-Barr virus (EBV) early protein EB2 is a posttranscriptional activator expressed under the control of EBV transcription factors EB1 and R. J Virol (1989) 2.20
The enhancer factor R of Epstein-Barr virus (EBV) is a sequence-specific DNA binding protein. Nucleic Acids Res (1990) 2.19
Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. Proc Natl Acad Sci U S A (1996) 2.18
A third viral nuclear protein in lymphoblasts immortalized by Epstein-Barr virus. Proc Natl Acad Sci U S A (1985) 2.16
The transforming domain alone of the latent membrane protein of Epstein-Barr virus is toxic to cells when expressed at high levels. J Virol (1989) 2.13
Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-kappaB activation. J Virol (1997) 2.05
A sixth Epstein-Barr virus nuclear protein (EBNA3B) is expressed in latently infected growth-transformed lymphocytes. J Virol (1988) 1.99
5-Azacytidine up regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt's lymphoma line rael. J Virol (1989) 1.99
Posttranslational processing of an Epstein-Barr virus-encoded membrane protein expressed in cells transformed by Epstein-Barr virus. J Virol (1987) 1.95
All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts. J Virol (1993) 1.92
An Epstein-Barr virus protein associated with cell growth transformation interacts with a tyrosine kinase. J Virol (1991) 1.90
The Epstein-Barr virus immediate-early gene product, BMLF1, acts in trans by a posttranscriptional mechanism which is reporter gene dependent. J Virol (1989) 1.86
Domains of the Epstein-Barr virus (EBV) transcription factor R required for dimerization, DNA binding and activation. Nucleic Acids Res (1991) 1.84
Functional limits of oriP, the Epstein-Barr virus plasmid origin of replication. J Virol (1989) 1.82
Epstein-Barr virus and human diseases: recent advances in diagnosis. Clin Microbiol Rev (1988) 1.78
Phenotypes of Epstein-Barr virus LMP1 deletion mutants indicate transmembrane and amino-terminal cytoplasmic domains necessary for effects in B-lymphoma cells. J Virol (1992) 1.77
Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines. Proc Natl Acad Sci U S A (1987) 1.77
Control of human B-lymphocyte replication. II. Transforming Epstein-Barr virus exploits three distinct viral signals to undermine three separate control points in B-cell growth. Immunology (1986) 1.75
An Epstein-Barr virus transformation-associated membrane protein interacts with src family tyrosine kinases. J Virol (1992) 1.74
Transcription of the Epstein-Barr virus genome during latency in growth-transformed lymphocytes. J Virol (1990) 1.74
Identification and characterization of murine gammaherpesvirus 68 gp150: a virion membrane glycoprotein. J Virol (1996) 1.64
Identification of Epstein-Barr virus terminal protein 1 (TP1) in extracts of four lymphoid cell lines, expression in insect cells, and detection of antibodies in human sera. J Virol (1990) 1.56
Complex transcription of the Epstein-Barr virus BamHI fragment H rightward open reading frame 1 (BHRF1) in latently and lytically infected B lymphocytes. Proc Natl Acad Sci U S A (1988) 1.47
Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP. J Virol (1988) 1.37
Transformation by the oncogenic latent membrane protein correlates with its rapid turnover, membrane localization, and cytoskeletal association. J Virol (1991) 1.37
Variable expression of latent membrane protein in nasopharyngeal carcinoma can be related to methylation status of the Epstein-Barr virus BNLF-1 5'-flanking region. J Virol (1991) 1.33
Posttranslational processing of the Epstein-Barr virus-encoded p63/LMP protein. J Virol (1987) 1.33
cis-acting regulatory elements near the Epstein-Barr virus latent-infection membrane protein transcriptional start site. J Virol (1990) 1.32
The Epstein-Barr virus (EBV) ORI1yt enhancer is not B-cell specific and does not respond synergistically to the EBV transcription factors R and Z. J Virol (1990) 1.29
Generation of specific cytotoxic T cells with a fragment of the Epstein-Barr virus-encoded p63/latent membrane protein. Proc Natl Acad Sci U S A (1987) 1.28
Interaction of tumor necrosis factor receptor-associated factor signaling proteins with the latent membrane protein 1 PXQXT motif is essential for induction of epidermal growth factor receptor expression. Mol Cell Biol (1998) 1.24
Characterization of two related Epstein-Barr virus-encoded membrane proteins that are differentially expressed in Burkitt lymphoma and in vitro-transformed cell lines. Proc Natl Acad Sci U S A (1986) 1.22
Nonresponsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implications for vaccine strategies. Proc Natl Acad Sci U S A (1991) 1.20
Biochemical characterization of Epstein-Barr virus nuclear antigen 2A. J Virol (1991) 1.14
Latent infection membrane protein transmembrane FWLY is critical for intermolecular interaction, raft localization, and signaling. Proc Natl Acad Sci U S A (2003) 1.14
Identification of the Epstein-Barr virus terminal protein gene products in latently infected lymphocytes. J Virol (1990) 1.14
Epstein-Barr virus gene expression in malignant lymphomas induced by experimental virus infection of cottontop tamarins. J Virol (1989) 1.11
Processing of the Epstein-Barr virus-encoded latent membrane protein p63/LMP. J Virol (1990) 1.07
Identification of a glucocorticoid-responsive element in Epstein-Barr virus. J Virol (1990) 1.05
B-cell lymphoproliferation and lymphomagenesis are associated with clonotypic intracellular terminal regions of the Epstein-Barr virus. J Virol (1988) 1.03
Host cell-dependent regulation of growth transformation-associated Epstein-Barr virus antigens in somatic cell hybrids. J Virol (1989) 0.96
Up regulation of the Epstein-Barr virus (EBV)-encoded membrane protein LMP in the Burkitt's lymphoma line Daudi after exposure to n-butyrate and after EBV superinfection. J Virol (1990) 0.95
Lymphocyte subsets in tumour of patients with undifferentiated nasopharyngeal carcinoma: presence of lymphocytes with the phenotype of activated T cells. Br J Cancer (1987) 0.88
LMP1 transmembrane domain 1 and 2 (TM1-2) FWLY mediates intermolecular interactions with TM3-6 to activate NF-kappaB. J Virol (2006) 0.87
Leukocyte migration inhibition demonstrates a human T-cell response to a membrane protein expressed in latent Epstein-Barr virus infection. J Virol (1986) 0.83
Epstein-Barr virus LMP1 modulates the malignant potential of gastric carcinoma cells involving apoptosis. Am J Pathol (1998) 0.83
Marked, transient inhibition of expression of the Epstein-Barr virus latent membrane protein gene in Burkitt's lymphoma cell lines by electroporation. J Virol (1993) 0.83
Presence of the diffuse early antigen of Epstein-Barr virus in lymphomas and lymphoproliferative disorders. Am J Pathol (1992) 0.81
Characterization of the latent membrane protein 1 signaling complex of Epstein-Barr virus in the membrane of mammalian cells with bimolecular fluorescence complementation. Virol J (2011) 0.78
Identification of transmembrane protein 134 as a novel LMP1-binding protein by using bimolecular fluorescence complementation and an enhanced retroviral mutagen. J Virol (2012) 0.78
Regulation of Latent Membrane Protein 1 Signaling through Interaction with Cytoskeletal Proteins. J Virol (2015) 0.76
The analysis of EBV proteins which are antigenic in vivo. Nucleic Acids Res (1988) 0.75
Colocalization of interferon regulatory factor 7 (IRF7) with latent membrane protein 1 (LMP1) of Epstein-Barr virus. J Korean Med Sci (2006) 0.75
High molecular weight complex analysis of Epstein-Barr virus Latent Membrane Protein 1 (LMP-1): structural insights into LMP-1's homo-oligomerization and lipid raft association. Virus Res (2013) 0.75
Maintenance of growth transformation with Epstein-Barr virus is mediated by secretion of autocrine growth factors in two serum-free B-cell lines. J Virol (1988) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A (1977) 790.54
"Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem (1981) 71.15
Beta-galactosidase gene fusions for analyzing gene expression in escherichia coli and yeast. Methods Enzymol (1983) 14.92
CYTOLOGY OF BURKITT'S TUMOUR (AFRICAN LYMPHOMA). Lancet (1964) 9.32
Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line. J Virol (1967) 8.29
Protein localization in E. coli: is there a common step in the secretion of periplasmic and outer-membrane proteins? Cell (1981) 8.24
Analysis of adenovirus transforming proteins from early regions 1A and 1B with antisera to inducible fusion antigens produced in Escherichia coli. J Virol (1984) 6.73
Structure of two spliced mRNAs from the transforming region of human subgroup C adenoviruses. Nature (1979) 6.60
Sequence of the lacZ gene of Escherichia coli. EMBO J (1983) 6.46
Transformation of foetal human keukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus. Int J Cancer (1968) 6.29
Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein. J Virol (1984) 5.87
Epstein-Barr virus RNA. V. Viral RNA in a restringently infected, growth-transformed cell line. J Virol (1980) 5.59
Continuous lymphoid cell lines with characteristics of B cells (bone-marrow-derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas. Proc Natl Acad Sci U S A (1974) 5.13
Epstein-Barr virus (B95-8) DNA VII: molecular cloning and detailed mapping. Proc Natl Acad Sci U S A (1980) 5.02
One of two Epstein-Barr virus nuclear antigens contains a glycine-alanine copolymer domain. Proc Natl Acad Sci U S A (1983) 4.94
An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology (1975) 4.48
Epstein-Barr virus DNA. IX. Variation among viral DNAs from producer and nonproducer infected cells. J Virol (1981) 4.38
Cytotoxic effector cells specific for B Cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis. Proc Natl Acad Sci U S A (1975) 4.21
Simple repeat array in Epstein-Barr virus DNA encodes part of the Epstein-Barr nuclear antigen. Science (1983) 4.04
Simple repeat sequence in Epstein-Barr virus DNA is transcribed in latent and productive infections. J Virol (1982) 2.51
Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res (1981) 2.25
Biological properties and viral surface antigens of Burkitt lymphoma- and mononucleosis- derived strains of Epstein-Barr virus released from transformed marmoset cells. J Virol (1976) 2.22
Mapping of polypeptides encoded by the Epstein-Barr virus genome in productive infection. Proc Natl Acad Sci U S A (1982) 2.20
Use of gene fusions and protein-protein interaction in the isolation of a biologically active regulatory protein: the replication initiator protein of plasmid R6K. Proc Natl Acad Sci U S A (1983) 2.14
Epstein-Barr virus superinduces a new human B cell differentiation antigen (B-LAST 1) expressed on transformed lymphoblasts. Cell (1982) 1.95
HLA-restricted T-cell recognition of Epstein-Barr virus-infected B cells. Nature (1980) 1.90
Primary structure of alpha-subunit of DNA-dependent RNA polymerase from Escherichia coli. FEBS Lett (1977) 1.87
A new tumour-derived transforming strain of Epstein-Barr virus. Nature (1978) 1.84
HLA antigen-related restriction of T lymphocyte cytotoxicity to Epstein-Barr virus. Proc Natl Acad Sci U S A (1980) 1.60
Induction and biological characterization of the Epstein-Barr virus (EBV) carried by the Jijoye lymphoma line. Virology (1980) 1.55
Characterization of an antigen whose cell surface expression is induced by infection with Epstein-Barr virus. J Virol (1983) 1.32
An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell (1985) 10.13
Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell (1991) 7.40
Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med (1989) 6.66
Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci U S A (1989) 6.32
Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol (1990) 6.23
The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell (1995) 5.97
Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci U S A (1993) 5.92
Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein. J Virol (1984) 5.87
Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad Sci U S A (1987) 5.68
Epstein-Barr virus RNA. V. Viral RNA in a restringently infected, growth-transformed cell line. J Virol (1980) 5.59
U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2. Proc Natl Acad Sci U S A (1984) 5.27
Nucleotide sequences of mRNAs encoding Epstein-Barr virus nuclear proteins: a probable transcriptional initiation site. Proc Natl Acad Sci U S A (1986) 5.12
Genetic relatedness of type 1 and type 2 herpes simplex viruses. J Virol (1972) 5.11
Epstein-Barr virus (B95-8) DNA VII: molecular cloning and detailed mapping. Proc Natl Acad Sci U S A (1980) 5.02
One of two Epstein-Barr virus nuclear antigens contains a glycine-alanine copolymer domain. Proc Natl Acad Sci U S A (1983) 4.94
Epstein-Barr virus RNA VII: size and direction of transcription of virus-specified cytoplasmic RNAs in a transformed cell line. Proc Natl Acad Sci U S A (1981) 4.77
Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol (1988) 4.55
Epstein-Barr virus DNA. IX. Variation among viral DNAs from producer and nonproducer infected cells. J Virol (1981) 4.38
Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood (1997) 4.36
Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J Virol (1990) 4.24
DNA of Epstein-Barr virus VIII: B95-8, the previous prototype, is an unusual deletion derivative. Cell (1980) 4.14
Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med (1992) 4.11
Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol (1993) 4.05
Simple repeat array in Epstein-Barr virus DNA encodes part of the Epstein-Barr nuclear antigen. Science (1983) 4.04
The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein. Proc Natl Acad Sci U S A (1994) 3.88
Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell (1987) 3.87
Proteins of Epstein-Barr virus. I. Analysis of the polypeptides of purified enveloped Epstein-Barr virus. J Virol (1976) 3.83
Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med (1992) 3.75
Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus. J Virol (1986) 3.65
Early events in Epstein-Barr virus infection of human B lymphocytes. Virology (1991) 3.60
A bicistronic Epstein-Barr virus mRNA encodes two nuclear proteins in latently infected, growth-transformed lymphocytes. J Virol (1987) 3.58
Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol (1990) 3.54
Deprivation payments revisited (again) BMJ (1996) 3.45
DNA of Epstein-Barr virus. IV. Linkage map of restriction enzyme fragments of the B95-8 and W91 strains of Epstein-Barr Virus. J Virol (1978) 3.41
Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. J Gen Virol (1987) 3.28
A second nuclear protein is encoded by Epstein-Barr virus in latent infection. Science (1985) 3.26
Epstein-Barr virus RNA. VIII. Viral RNA in permissively infected B95-8 cells. J Virol (1982) 3.26
Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation. J Virol (1991) 3.24
Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Mol Cell Biol (1996) 3.22
Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell (1992) 3.21
Epstein-Barr virus-induced genes: first lymphocyte-specific G protein-coupled peptide receptors. J Virol (1993) 3.19
Recombinant Epstein-Barr virus with small RNA (EBER) genes deleted transforms lymphocytes and replicates in vitro. Proc Natl Acad Sci U S A (1991) 3.17
Two related Epstein-Barr virus membrane proteins are encoded by separate genes. J Virol (1989) 3.09
Identification of polypeptide components of the Epstein-Barr virus early antigen complex with monoclonal antibodies. J Virol (1983) 3.06
Clinical features and natural history of Beckwith-Wiedemann syndrome: presentation of 74 new cases. Clin Genet (1994) 3.04
Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes (1999) 3.00
Cell lineages of the embryo of the nematode Caenorhabditis elegans. Proc Natl Acad Sci U S A (1978) 2.95
Oncogenic forms of NOTCH1 lacking either the primary binding site for RBP-Jkappa or nuclear localization sequences retain the ability to associate with RBP-Jkappa and activate transcription. J Biol Chem (1997) 2.93
Epstein-Barr virus-specific RNA. III. Mapping of DNA encoding viral RNA in restringent infection. J Virol (1979) 2.90
Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J Biol Chem (1996) 2.85
Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci U S A (1991) 2.82
The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. J Virol (1991) 2.81
Persistence of the entire Epstein-Barr virus genome integrated into human lymphocyte DNA. Science (1984) 2.77
DNA of Epstein-Barr virus. III. Identification of restriction enzyme fragments that contain DNA sequences which differ among strains of Epstein-Barr virus. J Virol (1978) 2.76
The truncated form of the Epstein-Barr virus latent-infection membrane protein expressed in virus replication does not transform rodent fibroblasts. J Virol (1988) 2.74
Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity (1995) 2.74
Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1. J Virol (1995) 2.71
Epstein-Barr virus DNA XII. A variable region of the Epstein-Barr virus genome is included in the P3HR-1 deletion. J Virol (1982) 2.70
Epidermal naevus in Proteus syndrome showing loss of heterozygosity for an inherited PTEN mutation. Br J Dermatol (2006) 2.63
DNA of Epstein-Barr virus. V. Direct repeats of the ends of Epstein-Barr virus DNA. J Virol (1979) 2.63
Definitive identification of a member of the Epstein-Barr virus nuclear protein 3 family. Proc Natl Acad Sci U S A (1986) 2.62
Restricted Epstein-Barr virus protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site. Proc Natl Acad Sci U S A (1991) 2.61
Chromosome site for Epstein-Barr virus DNA in a Burkitt tumor cell line and in lymphocytes growth-transformed in vitro. Proc Natl Acad Sci U S A (1983) 2.61
A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1. J Virol (1990) 2.60
Lymphoproliferative lesions of the ocular adnexa. Analysis of 112 cases. Ophthalmology (1998) 2.60
Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med (1997) 2.59
Identification of an Epstein-Barr virus early gene encoding a second component of the restricted early antigen complex. Virology (1987) 2.53
Simple repeat sequence in Epstein-Barr virus DNA is transcribed in latent and productive infections. J Virol (1982) 2.51
NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci U S A (2000) 2.48
Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation. Cell (1994) 2.48
Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus. J Exp Med (1994) 2.47
Epstein-barr virus-specific RNA. II. Analysis of polyadenylated viral RNA in restringent, abortive, and prooductive infections. J Virol (1977) 2.38
An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking. Proc Natl Acad Sci U S A (1994) 2.38
The Epstein-Barr virus nuclear protein 2 acidic domain forms a complex with a novel cellular coactivator that can interact with TFIIE. Mol Cell Biol (1995) 2.36
Long internal direct repeat in Epstein-Barr virus DNA. J Virol (1982) 2.36
A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J Virol (1996) 2.34
Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer (1997) 2.30
BHRF1, the Epstein-Barr virus gene with homology to Bc12, is dispensable for B-lymphocyte transformation and virus replication. J Virol (1991) 2.28
Expression of the Epstein-Barr virus nuclear protein 2 in rodent cells. J Virol (1986) 2.28
Epstein-Barr virus nuclear protein 2 transactivates a cis-acting CD23 DNA element. J Virol (1991) 2.28
A fifth Epstein-Barr virus nuclear protein (EBNA3C) is expressed in latently infected growth-transformed lymphocytes. J Virol (1988) 2.27
Maintenance of Epstein-Barr virus (EBV) oriP-based episomes requires EBV-encoded nuclear antigen-1 chromosome-binding domains, which can be replaced by high-mobility group-I or histone H1. Proc Natl Acad Sci U S A (2001) 2.26
Epstein-Barr virus RNA. VI. Viral RNA in restringently and abortively infected Raji cells. J Virol (1981) 2.26